Youcare Pharmaceutical Group (688658.SH) Subsidiary Receives Clinical Trial Approval for YKYY013 Injection

Stock News11-05

Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its subsidiaries, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. ("Youcare Kechuang") and Hangzhou Tianlong Pharmaceutical Co., Ltd. ("Hangzhou Tianlong"), recently obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for YKYY013 injection, intended for the treatment of chronic hepatitis B virus (HBV) infection. The company will proceed with Phase I clinical trials for this product.

YKYY013 injection is a chemically synthesized double-stranded siRNA drug independently developed by Youcare Kechuang and Hangzhou Tianlong, conjugated with N-acetylgalactosamine (GalNAc) ligands. It effectively silences the messenger RNA (mRNA) transcribed from the HBV genome through RNA interference, thereby inhibiting the production of HBV pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction. Ultimately, it aims to achieve functional cure for hepatitis B. The drug is intended for clinical use in treating chronic HBV infection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165737584?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 16:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165737584","market":"sg","top_or_hot":-1,"title":"Youcare Pharmaceutical Group (688658.SH) Subsidiary Receives Clinical Trial Approval for YKYY013 Injection","media":"Stock News","content":"<p>Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its subsidiaries, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (\"Youcare Kechuang\") and Hangzhou Tianlong Pharmaceutical Co., Ltd. (\"Hangzhou Tianlong\"), recently obtained the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA) for YKYY013 injection, intended for the treatment of chronic hepatitis B virus (HBV) infection. The company will proceed with Phase I clinical trials for this product.</p>\n<p>YKYY013 injection is a chemically synthesized double-stranded siRNA drug independently developed by Youcare Kechuang and Hangzhou Tianlong, conjugated with N-acetylgalactosamine (GalNAc) ligands. It effectively silences the messenger RNA (mRNA) transcribed from the HBV genome through RNA interference, thereby inhibiting the production of HBV pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction. Ultimately, it aims to achieve functional cure for hepatitis B. The drug is intended for clinical use in treating chronic HBV infection.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Youcare Pharmaceutical Group (688658.SH) Subsidiary Receives Clinical Trial Approval for YKYY013 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYoucare Pharmaceutical Group (688658.SH) Subsidiary Receives Clinical Trial Approval for YKYY013 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-05 16:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its subsidiaries, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (\"Youcare Kechuang\") and Hangzhou Tianlong Pharmaceutical Co., Ltd. (\"Hangzhou Tianlong\"), recently obtained the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA) for YKYY013 injection, intended for the treatment of chronic hepatitis B virus (HBV) infection. The company will proceed with Phase I clinical trials for this product.</p>\n<p>YKYY013 injection is a chemically synthesized double-stranded siRNA drug independently developed by Youcare Kechuang and Hangzhou Tianlong, conjugated with N-acetylgalactosamine (GalNAc) ligands. It effectively silences the messenger RNA (mRNA) transcribed from the HBV genome through RNA interference, thereby inhibiting the production of HBV pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction. Ultimately, it aims to achieve functional cure for hepatitis B. The drug is intended for clinical use in treating chronic HBV infection.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1165737584","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165737584","pubTimestamp":1762330692,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its subsidiaries, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (\"Youcare Kechuang\") and Hangzhou Tianlong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"优康药业集团（688658.SH）子公司YKYY013注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1},"content_text":"Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its subsidiaries, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (\"Youcare Kechuang\") and Hangzhou Tianlong Pharmaceutical Co., Ltd. (\"Hangzhou Tianlong\"), recently obtained the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA) for YKYY013 injection, intended for the treatment of chronic hepatitis B virus (HBV) infection. The company will proceed with Phase I clinical trials for this product.\nYKYY013 injection is a chemically synthesized double-stranded siRNA drug independently developed by Youcare Kechuang and Hangzhou Tianlong, conjugated with N-acetylgalactosamine (GalNAc) ligands. It effectively silences the messenger RNA (mRNA) transcribed from the HBV genome through RNA interference, thereby inhibiting the production of HBV pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction. Ultimately, it aims to achieve functional cure for hepatitis B. The drug is intended for clinical use in treating chronic HBV infection.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165737584","isCrawlerRequest":true}